STUDIES VALIDATE PERFORMANCE OF PALL PRION REDUCTION TECH.

(From Asia Pulse)

(Full text of a statement. Contact details below)

EAST HILLS, N.Y.--(BUSINESS WIRE)--Oct. 17, 2005--Research studies demonstrating the effectiveness of prion filtration technology to safeguard the blood supply are being presented at the AABB Annual Meeting in Seattle, Washington, today.

Prion diseases, such as variant Creutzfeldt-Jakob Disease (vCJD), the human form of Bovine Spongiform Encephalopathy or "mad cow" disease, are of growing concern to blood services worldwide because of the potential for transmission through transfusion from asymptomatic donors. Pall Corporation (NYSE: PLL) is presenting research results further validating the performance of its Leukotrap(R) Affinity Prion Reduction Filter System, which was CE marked with a 99.9 per cent prion removal efficiency in May …